Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Université Paris-Sud · Institut Gustave Roussy · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,958
total citations
- FWCI
- 105.46
- Percentile
- 100%
- References
- 37
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Medicine
- Denosumab
- Zoledronic acid
- Prostate cancer
- Clinical endpoint
- Internal medicine
- Oncology
- Placebo
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.